[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583412":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Brexpiprazole (Rexulti)","In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[20],{"facility":21,"status":22,"city":23,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan","JP",{"type":28,"coordinates":29},"Point",[30,31],135.50107,34.69379,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":17,"phoneExt":7,"email":18},"Study Director",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100583412","rexulti-drug-general-use-results-survey-excessive-motor-activity-or-physicallyverbally-aggressive-behavior-due-to-rapid-changes-in-mood-irritability-andor-outbursts-associated-with-dementia-due-to-alzheimers-disease-100583412",false,"NCT06875986","REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically\u002FVerbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and\u002For Outbursts Associated With Dementia Due to Alzheimer's Disease)","Inclusion Criteria:\n\n* Patients diagnosed with Alzheimer's disease\n\nExclusion Criteria:\n\n\\-","ALL","15 Years",{"count":47,"type":48},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.",[52],"Alzheimer Disease","2025-06-27",{"date":55,"type":56},"2025-07-02","ACTUAL",{"date":58,"type":56},"2025-04-17",{"date":60,"type":48},"2028-09-23",{"name":5,"class":6},1]